NMC Healthcare is UAE’s largest private healthcare provider. It has two main branches of business, NMC Healthcare and NMC Trading.
From a one room clinic in Abu Dhabi to a global healthcare enterprise in 40 years – this is the journey called NMC.
Since its inception, NMC has been chalking out distinct growth strategies that reflect the continuing leadership in the market. Having focused on expanding the capacities and building new capabilities, NMC has developed specialised verticals covering multi-specialty care, maternity and fertility, long-term and home care, operations and management and distribution services.
Over the years, NMC has earned the trust of millions, thanks to its personalised care and a sincere commitment to the overall well-being of the community it serves.
With a team of over 2,000 doctors and 18,000 paramedical and support personnel, NMC owns and manages over 135 healthcare facilities that includes hospitals, medical centres, long term care facilities, day surgery centres, fertility centres and home health services providers.
Every year, over 8.5 million patients are treated by NMC doctors across UAE, Saudi Arabia, Kuwait, Oman, UK, Spain, Italy, Denmark, Slovakia, Egypt, Brazil and Colombia.
NMC was the first company from Abu Dhabi to list on the London Stock Exchange and is now part of the FTSE 100 Index, an elite club of top 100 blue-chip companies by market cap.

Broker Forecast - JP Morgan Cazenove issues a broker note on NMC Health PLC
BFN
JP Morgan Cazenove today reaffirms its neutral investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4060p (from 3270p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk

10:00 22/08/2018
Broker Forecast - Barclays Capital issues a broker note on NMC Health PLC
Barclays Capital today reaffirms its top pick investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4850p (from 4600p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

21 Sep
Barclays...
N/A
Overweight
22 Aug
Barclays...
4,850.00
Top pick

i hold a few of these in my sipp, and thus with a fairly long term view
it's certainly a dangerous stock to try to trade as the chart shows, for it can be horribly volatile for no apparent reason

There was another UAE hospital/ health care provider I opened a thread for at the same time. I think they changed the company name, but this one has out performed it. Yes can be volatile.

Mediclinic International Plc (MDC) found it.

Not sure you will have heard of this company dream , but it has promise , it's called Versarien , AGM on Tues 25th , keep it to yourself as it could rocket soon .

Who are they? I hope you filled your boots on the normal pullback.

Suppose I should have learnt that by now , I'll have to get into this profit taking mentality , see it's on it's way back up now , it's the fear of news coming pre agm .

Playing with all profit only now, Which we all must have a very good balance. :-))

Going to be an interesting afternoon. Hold your hats on.lol

Capital Markets Day & Positively Revised Guidance
RNS
RNS Number : 6831E
NMC Health Plc
22 October 2018

22 October 2018

NMC Health plc
(the "Company" or "NMC")

Capital Markets Day and Positively Revised Guidance

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, announces that the Company will be holding a Capital Markets Day today at the London Stock Exchange.

Prashanth Shenoy, Chief Financial Officer of NMC Health, will provide an update on guidance given in January, following positive developments in the second half of 2018. As a result, we now anticipate an increase of 2% in revenue growth from 22% to 24% and an increased EBITDA guidance from $465m to $480m by year-end 2018.

2019 guidance will also point towards continuation of strong organic growth on the back of sustained ramp-up at key facilities, integration and expansion of acquired entities as well as strong operational performance. Revenues are forecast to increase by 22-24% and EBITDA is expected to increase by 18-20%. 2019 guidance does not include the effects of implementation of IFRS 16. The guidance also does not reflect the impact of anticipated financial consolidation of National Medical Care Company. An update in this regard will be provided once the joint-venture with Hassana/GOSI has been formalized, which is on track for completion during Q4 18.

During the year 2019, management also anticipates: 1) opening of new greenfield facilities, particularly in UAE, 2) continued ramp-up of various facilities across multiple geographies and 3) full-year consolidation of Aspen Healthcare, all of which will impact EBITDA margin.

Management remains confident on the longer-term margin guidance for the Company and NMC remains on track to achieve 25% EBITDA margin by 2020/2021.

10:00 23/10/2018
Broker Forecast - HSBC issues a broker note on NMC Health PLC
HSBC today reaffirms its buy investment rating on NMC Health PLC (LON:NMC) and raised its price target to 4600p (from 1430p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Purchase of Shares
RNS
RNS Number : 8923F
NMC Health Plc
31 October 2018



NMC Health plc

Purchase of Shares


London, 31 October 2018: NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, received notification from Jonathan Bomford, the Senior Independent Director of the Company, that on 31 October 2018 he bought through his SIPP, 1,000 ordinary shares of 10p each in the Company ("Shares") at a price of 3475.545p pence per share.

Following this transaction, Jonathan Bomford's share interest, including the shares held by his spouse, has increased to 20,000 Shares, representing approximately 0.01% of the issued share capital of the Company.

a good healthcare company based in m/e, so not quite as susceptible to uk jitters
nevertheless, it can be quite volatile

have just topped up my sipp to an "average" holding

and a nice rise today of 6% perhaps on the back of an upgrade from jpm

Hopefully back above £40 :-))

09:50 27/11/2018
Broker Forecast - Jefferies International issues a broker note on NMC Health PLC
Jefferies International today downgrades its investment rating on NMC Health PLC (LON:NMC) to underperform (from hold) and cut its price target to 2940p (from 3411p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk

Trading Update
RNS
RNS Number : 8932J
NMC Health Plc
10 December 2018

10 December 2018

NMC Health plc
(the "Company" or "NMC")

Trading Update: Reiterating 2018 & 2019 financial guidance; delivering further positive operational progress

Strong growth is underpinned by NMC's strategy of focusing on business segments well beyond multi-specialty, a wide geographic footprint in its target markets and offering healthcare for all segments

H2 cash flow improved as actions taken to normalize receivables continue to yield results

KPIs for management LTIP revised to better align with shareholder value creation

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 17 countries, maintains its positive outlook for the remainder of 2018, as well as 2019.

Management remains comfortable with and reiterates guidance for 2018 and 2019

Given the combination of NMC's strategy, supportive underlying industry dynamics and continued positive operational developments, management remains comfortable with the financial guidance it provided for 2018 and 2019 at its recent Capital Markets Day. Of particular note is the continued roll out of insurance coverage in NMC's core markets, including the completion of the mandatory insurance program last year in Dubai. Guidance remains as follows:

FY 2018 Guidance:

- +24% YoY revenue growth
- Organic revenue growth approximately 15% for the year
- +36% YoY growth in EBITDA to USD 480m
- Year-end net-debt to EBITDA to stand at c. 3.0x

FY 2019 Guidance:

- +22-24% YoY revenue growth
- +18-20% YoY EBITDA growth
- Excluding impact of acquisitions completed in 2018, FY 2019 revenue growth is anticipated to be 12-13% YoY and EBITDA growth approximately 15% YoY
- Year-end net-debt to EBITDA to further reduce to 2.2-2.4x
- 2019 guidance does not include impact of IFRS 16 implementation or the anticipated consolidation of National Medical Care Co.

Receivables collection normalizing in H2 2018, positively impacting cash flows

As highlighted in the half-year results announcement, H1 2018 witnessed slight extension of receivable days outstanding due to slower receivables collection for the Distribution business as a result of extended holidays towards the end of the first half. As anticipated, receivables collection continues to normalize in the second half of the year, with a decline in receivable days outstanding in H2 2018. This continues to positively impact NMC's cash flow generation for the year.


KSA joint-venture progressing well, final agreement expected to be signed in early Q1 2019

Discussions with GOSI/Hassana for the finalization of the KSA JV continue to progress well, with the final agreement expected to be signed in early Q1 2019. The joint-venture was also showcased at the recently held Future Investment Initiative conference as one of the most prominent ongoing developments in the healthcare sector in KSA. As highlighted in our Capital Markets Day, the JV intends to double its initial bed capacity of c. 1,500 beds to approximately 3,000 in 3-5 years, followed by a further doubling of capacity to around 6,000 beds in 5-10 years.

Operations & Management (O&M) vertical continues to expand with signing of new contracts

NMC has signed a new O&M contract with the UAE Ministry of Presidential Affairs (MOPA) to manage a hospital in Seychelles. In addition, the Company continues to add a number of smaller, but strategic, O&M contracts in the UAE, which significantly support NMC's profile and visibility. A key recent example includes the signing of a contract to manage the medical clinic in Louvre Museum, Abu Dhabi. The Company similarly manages clinics in prominent locations such as the Grand Mosque in Abu Dhabi and the Court of the Crown Prince.

As highlighted earlier, in addition to providing some of the highest margin revenues, O&M contracts offer NMC the opportunity to gain experience in new market segments and geographies without risking its own capital. O&M contracts are now supporting business activity in other verticals as well. For example, both the Yemen and Kenya O&M contracts have become important sources of high-complexity patient referral to NMC Royal.

KPIs for management LTIP revised for better alignment with shareholder value creation

Based on the feedback received from key independent, institutional shareholders during recent meetings, NMC has opted to revise KPIs for management LTIP to better align with shareholder value creation. Consequently, the Remuneration Committee has determined to:

- Increase the EBITDA growth performance requirement for 2019 LTIP awards from 5% - 15% to 10% to 18% (CAGR) at threshold and maximum respectively.

- Introduce an additional underpin capturing the conversion of EBITDA to net income, to provide shareholders with an aggregate view on earnings, cash flow, and capital efficiency. Failure to meet the underpin will reduce the proportion of 2019 LTIP awards vesting by 50%.

The Remuneration Committee re-iterates that STIP and LTIP incentive targets are adjusted for acquisitions and other corporate activity on a case by case basis. Full disclosure of target adjustments will be provided in the 2018 Directors' Remuneration Report.

Mr Prasanth Manghat, Chief Executive Officer, commented:
"I am pleased that NMC's operations continue to perform very strongly, as reflected by our confidence in the reiterated financial guidance we have provided for 2018 and 2019. NMC's sustained growth is driven by a combination of 1) our strategy of offering complex, high value services well beyond simple multi-specialty, 2) maintaining an expansive footprint in our target markets, particular in the UAE where we are the only private player present in 6 of the 7 emirates and 3) offering healthcare for all, with no specific focus on one economic segment of patients. We continue to capitalize on new opportunities, as evidenced by the newly signed O&M contract with MOPA to manage a hospital in Seychelles. Furthermore, the importance NMC gives to views expressed by its owners is demonstrated by the revision of KPIs for management to bring them more in line with shareholder value creation. This was done in response to feedback we recently received from key independent shareholders."

BFN
Salma Hareb, Non Executive Director, bought 5,500 shares in the company on the 24th December 2018 at a price of 2699.07p. The Director now holds 12,100 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.sharesmagazine.co.uk